Ann Bass - Concepedia

Author

Ann Bass

Urology San Antonio

Also Known As

A Bass, A D Bass, A. Bass, Ann Bass, Ann D Bass, Ann D. Bass, Ann Doan-Do Bass, Bass, Ann, Mark A. Agius

Publications

Citations

H-Index

Concepts

All Affiliations

Urology San Antonio Sanofi (United States)University of British Columbia University of Southern California University Hospital Carl Gustav Carus

About

Ann Bass is an author at Urology San Antonio specializing in medicine, neuroimmunology, and multiple sclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.1K
2	Cell Biology	2	2	57
3	Health Sciences	1	1	896
4	Allergy	1	1	47
5	Cellular Physiology	1	1	10

Ann Bass

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial Alasdair Coles, Edward Fox, Anton Vladić, Neurology	2012	260
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes Alasdair Coles, Edward Fox, Anton Vladić, The Lancet Neurology RheumatologyClinical Efficacy OutcomesAutoimmune DiseaseDisease ProgressionMedicine	2011	138
Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Moshe Z. Papa, Ann Bass, R Adar, PubMed	1992	81
The T4 surface antigen is involved in the induction of helper function. L Rogozinski, Ann Bass, E Glickman, The Journal of Immunology	1984	77
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Tjalf Ziemssen, Ann Bass, Regina Berkovich, CNS Drugs	2020	55
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management Adam Cuker, Ann Bass, Čongor Nadj, Multiple Sclerosis Journal	2019	54
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships Ann Bass, Bart Van Wijmeersch, Lori Mayer, International Journal of MS Care	2019	54
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 Brian Steingo, Yaser Al Malik, Ann Bass, Journal of Neurology	2020	52
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients Amy E. Lovett‐Racke, Matthew Gormley, Yue Liu, Journal of Neuroimmunology Adaptive Immune SystemT-regulatory CellImmunologyImmune RegulationPathology	2019	47

Page 1